Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
TRETINOIN
BAUSCH HEALTH, CANADA INC.
D10AD01
TRETINOIN
0.1%
CREAM
TRETINOIN 0.1%
TOPICAL
30 G
Prescription
CELL STIMULANTS AND PROLIFERANTS
Active ingredient group (AIG) number: 0112395004; AHFS:
APPROVED
1999-02-02
_Pr_ _RETIN-A_ _®_ _ Product Monograph Page 1 of 21_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR RETIN-A ® Tretinoin Cream and Gel, Mfr. Std. Gel 0.025% w/w and 0.01% w/w Cream 0.1% w/w, 0.05% w/w, 0.025% w/w and 0.01% w/w COMEDOLYTIC AGENT BAUSCH HEALTH, CANADA INC. 2150 St-Elzear Blvd. West Laval (Quebec) H7L 4A8 Canada DATE OF REVISION: January 24, 2022 Submission Control Number: 255590 ® Registered trademark used under license of Bausch Health Companies. _Pr_ _RETIN-A_ _®_ _ Product Monograph Page 2 of 21_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 3 1 INDICATIONS.............................................................................................................. 3 1.1.1 Pediatrics ........................................................................................................ 3 1.1.2 Geriatrics ........................................................................................................ 3 2 CONTRAINDICATIONS ............................................................................................... 3 4 DOSAGE AND ADMINISTRATION .............................................................................. 3 4.2 Recommended Dose and Dosage Adjustment .................................................... 3 4.4 Administration..................................................................................................... 4 5 OVERDOSAGE ........................................................................................................... 4 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ........................ 4 7 WARNINGS AND PRECAUTIONS .............................................................................. 5 7.1 Special Populations ........... Izlasiet visu dokumentu